FDA cybersecurity hold letter response - reviewer-format package, 180-day clock owned end-to-end.
If the FDA raises a cybersecurity question, we answer it at no extra cost until the cybersecurity portion is closed.
275+ devices supported · No cybersecurity-related rejections to date
A cybersecurity hold stops your 510(k), De Novo, or PMA review until the FDA gets satisfactory answers. We move on hold letters in days, not months, with a fixed-fee closure quote back in your inbox within 24 hours of the call.
Free 30-min call · Senior US expert · Mutual NDA before the call
Last updated
“Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind; it gave us confidence that we were submitting exactly…”
Scott Odland, Solutions Architect, Rhaeos
Trusted by medical device teams worldwide
Premarket to postmarket. One senior team owns every cybersecurity artifact the FDA reviewer will open.
Senior reviewer reads your letter, maps every finding to required artifacts, and returns a written closure plan with effort estimate.
Every response is written against the February 2026 final premarket cybersecurity guidance and Section 524B(b)(1)-(3).
Updated cybersecurity content drops directly into eSTAR - no reformatting, no missing attachments, no second hold.
We pen-test, threat-model, and update only what the FDA asked about - fastest path to lifting the hold.
Cover letter and redlines structured the way cybersecurity reviewers want: finding → response → evidence → page reference.
One quote covers the response and any follow-up exchanges with the FDA until the cybersecurity hold is lifted.
Hold letters cluster around a handful of recurring asks. Recognizing the pattern in yours shortens the response cycle.
Single-device STRIDE submissions are getting held for missing fleet-level harm analysis. Most common ask under the February 2026 final guidance.
Component list without affected/not-affected/fixed/under-investigation status for each listed CVE is the second most common hold trigger.
524B(b)(1) requires a written description of how patches reach fielded devices. Verbal process descriptions get held; controlled outputs don't.
Reviewers want to see each pen test finding traced back to a threat-model entry. Standalone pen test reports get held for traceability.
What you actually get versus a generic regulatory consultant or a re-spin in-house while the clock burns.
| Capability | Blue Goat Cyber | Generic regulatory consultant | In-house |
|---|---|---|---|
| Hold-letter response track record | Routine - written for the reviewer who sent it | Treats hold like any other AI letter | First time under hold pressure |
| Speed under deadline | Reviewer-ready package in 2-4 weeks | Hourly, drifts with scope | Competes with launch work |
| Point-by-point response mapping | Mirrors hold-letter exactly | General rewrite, items missed | Built from scratch under pressure |
| Evidence package | Updated SPDF + SBOM/VEX + threat model + pen test | Documentation only, no fresh testing | Multiple owners, integration gaps |
| Pricing model | Fixed fee, revisions included | Hourly + change orders | Hidden internal cost |
We sign a mutual NDA before the initial call, then walk through your submission, the FDA findings, and the path to close them.
You receive a point-by-point response strategy mapped to Section 524B and the FDA February 2026 final guidance, plus a fixed-fee quote.
Updated SPDF, SBOM/VEX, threat model, targeted pen test, and cover letter - formatted the way FDA cybersecurity reviewers expect in eSTAR.
"Blue Goat's niche expertise in FDA-facing cybersecurity made all the difference. Their reports were built with the FDA's expectations in mind; it gave us confidence that we were submitting exactly what reviewers want to see."
If the FDA raises a cybersecurity deficiency, we fix it at no additional cost. 275+ devices supported.
We sign a mutual NDA before the initial call so you can share device details, architecture, and FDA correspondence freely.
No sales pressure. After the call, you get a concrete written strategy mapped to Section 524B and the FDA February 2026 final guidance.
Senior-led delivery on every FDA-facing artifact. No offshoring, no hourly billing. Revisions included. Every artifact is eSTAR-ready.
Who you're talking to
MBA, CISSP · U.S. Air Force Academy graduate · 30+ years in cybersecurity
Christian leads the senior medical device cybersecurity team behind 275+ devices supported. Author of three books including Medical Device Cybersecurity: An In-Depth Guide.
30-minute call with a senior medical device cybersecurity expert. Fixed-fee quote to lift the hold within 24 hours of the call.
